Brain MRI, lumbar CSF monoamine concentrations, and clinical descriptors of patients with spinocerebellar ataxia mutations


Abstract

Objectives—To serially assess changes in lumbar CSF biogenic amines, radiographic characteristics, and neurological signs in 34 patients with dominantly inherited ataxia.

Methods—Mutational analysis was used to identify genetic subgroups. Annual assessment of lumbar CSF monoamine metabolites using a gas chromatographic/mass spectrometric method and morphometric measurements of the cerebellum, pons, and the cervical spinal cord on MRI were analysed for each patient and compared with normal controls.

Results—Patients with CAG trinucleotide repeat expansions on chromosome 6p (mutSCA1) and chromosome 14q (mutSCA3) had only about one half the normal concentrations of lumbar CSF homovanillic acid (HVA) whereas, 5-hydroxyindoleacetic acid (5-HIAA) concentrations were similar to those in age matched normal subjects. The HVA and 5-HIAA concentrations in clinically similar patients without mutSCA1 or mutSCA3 were normal. One year after the first study, HVA concentrations were reduced by a mean of 22% regardless of the patient’s SCA mutation. Abnormalities on MRI were consistent with a spinopontine atrophy in patients with mutSCA3, spinopontocerebellar atrophy in patients with mutSCA1, and “pure” cerebellar atrophy in patients without these mutations.

Conclusions—Quantitative MRI measurements were not useful in monitoring progression of disease but lumbar CSF HVA concentrations and total scores on a revised version of the ataxia clinical rating scale seemed to progress in parallel.

Keywords: spinocerebellar degeneration; cerebellar ataxia; biogenic monoamines; nuclear magnetic resonance

Six genotypes have been assigned to a group of neurodegenerative disorders called the autosomal dominant ataxias.1-5 Two of these disorders are characterised by an expanded CAG trinucleotide repeat at the SCA1 locus on chromosome 6p1 (mutSCA1) and at the SCA3 locus on chromosome 14q (mutSCA3).1-5,10 Few studies have evaluated lumbar CSF monoamine metabolites or quantitative MRI abnormalities in groups of patients with dominantly inherited ataxia.11-16 Thus the results of clinical studies performed before the discovery of mutSCA1 and mutSCA3 are difficult to interpret. Patients with dominantly inherited ataxia and “pure” cerebellar cortical atrophy on MRI have low lumbar CSF concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA).16 By contrast, necropsy specimens from patients with mutSCA1 show low concentrations of striatal HVA with normal to increased striatal concentrations of 5-HIAA.17,18 Before products containing L-tryptophan were associated with the eosinophilia-myalgia syndrome,19 the serotonin precursor, L-5-hydroxytryptophan (5-L-HTP) was found to be an ineffective treatment for patients with dominantly inherited ataxia (Schut-Haymaker type and Machado-Joseph disease). As expected from the lumbar CSF monoamine profile, 5-L-HTP did improve static ataxia symptoms in patients with an MRI diagnosis of “pure” cerebellar cortical atrophy and a clinical diagnosis of Harding-ADCA type III.18,20 However, despite a depletion of striatal dopamine and lumbar CSF HVA, levodopa treatment did not ameliorate ataxic symptoms in patients with dominantly inherited ataxia.21-22 The distinct lack of parkinsonian signs in many patients with mutSCA1 and mutSCA3 implies that dopamine deficiency is not great but suggests that a dopaminergic deficit does play a part in the pathogenesis of these genetic disorders. Even though the gross postmortem neuropathology correlates well with the radiological features of patients with ataxia,14-15 evaluating patients in treatment groups categorised by MRI findings is unsatisfactory as it ignores genetic heterogeneity. To clarify the topography of MRI lesions and to define the monamine abnormalities in patients with SCA mutations, we longitudinally quantified atrophic changes on MRI, measured lumbar CSF monoamine metabolites, and objectively assessed neurological examinations on a revised version of the ataxia clinical rating scale (ACRS-rev).24-26

Materials and methods

PATIENT SELECTION AND CLINICAL TESTING

Informed consent was obtained from each patient before all genetic, radiological, and clinical tests. This study was approved by the
**Figure 1** Representative T1 weighted MRI images (TR = 400 ms, TE = 16 ms) displayed on the image analyser monitor showing the boundaries used to calculate (A) the medio-sagittal areas of the cerebellum,pons and posterior fossa and (B) the axial area of the cervical spinal cord.

Institutional Review Board of the National Institute of Neurological Disorders and Stroke. Investigators were blinded from the genetic profiles of asymptomatic subjects. Patients from families with ataxia for three or more consecutive generations were recruited by the Neurogenetics Unit. JHJ performed all neurological examinations and was blinded to the ACRS scores when the patients were re-evaluated at yearly intervals. The ACRS was revised to account for the progressive loss of tone and reflexes in our population patients by assigning positive scores for decreases in these items (ACRS-rev).

**ASSAY OF CSF HVA AND 5-HIAA**

After five days on a standard low monoamine diet and after eight hours of bed rest, a lumbar puncture was performed in the lateral decubitus position. Routine CSF studies were performed on the initial 4 ml CSF; for assay of HVA and 5-HIAA an additional 10 ml was collected in four 2.5 ml aliquots. All aliquots of CSF were frozen immediately on dry ice and stored at −70°C. To minimise the effects of CSF monoamine concentration gradients, the fourth aliquot of CSF was used for analysis. Extraction, derivatisation, and measurement of HVA and 5-HIAA were performed as previously described on a Hewlett Packard MSD 5970 mass spectrometer/gas chromatograph 5890 with preserved acid extracts of CSF supernatant liquid. The investigators (JDH-W, IJK) analysing the CSF samples were blinded to the patient’s clinical and genetic information.

**GENETIC TESTING**

A pair of fluorescein labelled oligonucleotides flanking the genetic region of interest were used in the polymerase chain reaction to amplify the CAG triplet repeats on chromosomes 6p and 14q as previously described.9

**MRI MORPHOLOGICAL MEASUREMENTS**

Brain MRI was performed twice at a one year interval, using a 0.5 Tesla unit scanner (Picker International Inc, model HPQ). Three 5.0 mm mediosagittal images were obtained parallel to the longitudinal fissure. The axial area of the cervical spinal cord (CSC; perpendicular to the first cervical vertebra) and the medio-sagittal areas of the pons (P; an elliptical pontine area bounded by the anterior surface of the pons, the interpeduncular fossa, and the putative medial lemniscus), cerebellum (Cb) and the posterior fossa (PF; a quadrangular area bounded by the tentorium cerebelli, the inner table of the skull, and the clivus) were quantified using ANALYZE™ version 6-2 software (Biomedical Imaging Resources, Mayo Foundation, Rochester, MN) on a DIGITAL™ DEC station 5000/125 (fig 1). Two investigators (MJC, TAG) were blinded to the ACRS scores and the genetic testing results at the time of the MRI analysis. Triplicate measurements of each neuroanatomical area were used to calculate the mean area in pixels. The size of the Cb and P were expressed as a ratio to the PF to adjust for variations in head size. Identical areas from 10 normal volunteers were used for comparisons with study participants.

**STATISTICS**

StatView™ version 4-01 software (Abacus Concepts, Inc, Berkeley, CA, USA) was used to compute all statistics. Differences between groups were examined by the Wilcoxon signed rank test.28 A simple regression model using measures obtained at the beginning of the study as predictor variables and the measurements of these variables one year later as the outcome variables was applied to the data. Residual values were plotted against the predicted values to verify the accuracy of the regression equations. The Bonferonni method was applied to adjust the α level according to the number of comparisons that were tested.59
Results

SERIAL CLINICAL FINDINGS

There were two families with mutSCA1, five with mutSCA3, and three without mutSCA1 or mutSCA3 included in the study. Four of the six members from one family and two of three members from another family without mutSCA1 or mutSCA3 had the clinical features of Harding ADCA type III. However, the four remaining members from these families without mutSCA1 or mutSCA3 had the neurological signs (supranuclear gaze palsy, dementia, and extrapyramidal signs) associated with Harding ADCA type I. All the families, regardless of genotype, exhibited the phenotypic variability seen in Harding ADCA type I. Neurological findings on the ACRS were similar in the 34 patients (mutSCA1, n = 7; mutSCA3, n = 17; without mutSCA1 or mutSCA3, n = 10) examined. All patients had gait ataxia varying from mild to severe. Cranial nerve findings included dysarthria, nystagmus, macular exudates, and supranuclear gaze palsy. Slowed saccadic movements, tongue fasciculations, and coughing dyspnea. Retinoschisis and Parkinson’s syndrome were present in one family without mutSCA1 or mutSCA3 but these features were not found in any of the patients involved in the MRI or CSF analyses. Deep tendon reflexes and muscle tone ranged between extremes. Sensation in the limbs varied from normal to complete loss of position and pain sensation. Limb atrophy, myoclonus, and scoliosis also varied. There were no significant differences in sex, disease duration, age at onset of disease, or total ACRS-rev scores between patients with mutSCA1, mutSCA3, or those patients without these mutations. At the onset of the study, patients without mutSCA1 or mutSCA3 were older (63.6 (3.3), mean (SEM)) than patients with mutSCA1 (35.8 (2.3)) and mutSCA3 (47.1 (3.0)). In patients that were examined at a yearly interval (n = 14), the initial total score on the ACRS-rev was 27 (5) and one year later it was significantly (P = 0.001) worse at 45 (7). In patients with mutSCA3 (n = 11), the initial total score was 34 (8) and was also significantly (P = 0.02) worse one year later at 55 (10). As predicted by a simple regression model, the initial total ACRS-rev scores changed 14 to 16 points in one year in all patients regardless of genotype (fig 2A).

MONOAMINE METABOLITES

The opening pressure, protein, glucose, and the micros copical appearance of the CSF was normal in all subjects. Lumbar CSF HVA concentrations were about 54% to 55% lower in patients with mutSCA1 (n = 7) and mutSCA3 (n = 15), but 5-HIAA concentrations were not significantly different from those of normal subjects (n = 20). The ratio of HVA to 5-HIAA was significantly (P < 0.01) lower in patients with mutSCA3 than in controls suggesting a monoaminergic neurotransmitter imbalance (table). A second lumbar puncture was performed on nine patients one year after the initial one. In these patients, lumbar CSF HVA concentrations decreased significantly (P < 0.01) by 22 (range 0–42%). Regression analysis predicted a relation between the initial lumbar CSF HVA concentrations and concentrations one year later (fig 2B).

FINDINGS ON MRI

Two independent blinded investigators quantified the areas of the Cb P, PF, and CSC on 1176 MRI images. In patients without mutSCA1 or mutSCA3 (n = 7), quantitative MRI findings were consistent with a cerebellar atrophy (Cb/PF = 65.3 (4.6); % normal
Lumbar CSF monoamine metabolites in normal subjects and in patients with SCA mutations

<table>
<thead>
<tr>
<th>Genotype</th>
<th>HVA (ng/ml)</th>
<th>5-HIAA (ng/ml)</th>
<th>Rate HVA/5-HIAA</th>
</tr>
</thead>
<tbody>
<tr>
<td>mutSCA1 (7)</td>
<td>18 (2.69) (10-91-31-46)*</td>
<td>11-67 (2-90) (5-93-22-52)</td>
<td>1-61 (0-35) (1-09-2-02)</td>
</tr>
<tr>
<td>mutSCA3 (15)</td>
<td>17 (2.64) (4-62-44-00)**</td>
<td>13-52 (1-14) (5-44-21-66)</td>
<td>1-38 (0-18) (0-28-2-94)**</td>
</tr>
<tr>
<td>Other (9)</td>
<td>41 (2.71) (8-68-08-67)</td>
<td>18-26 (3-27) (5-34-22-92)</td>
<td>2-05 (0-21) (1-10-2-85)</td>
</tr>
<tr>
<td>Total (30)</td>
<td>24.06 (3.07) (4-62-68-67)</td>
<td>14-51 (1-18) (5-34-32-29)</td>
<td>1-65 (0-12) (0-28-2-94)*</td>
</tr>
<tr>
<td>Normal (20)</td>
<td>39.08 (3-02) (17-03-61-50)</td>
<td>17-26 (1-26) (6-67-26-40)</td>
<td>2-30 (0-12) (1-50-3-39)</td>
</tr>
</tbody>
</table>

Values are mean (SEM) (range).
* P < 0-05; ** P < 0-01. Significantly lower compared with normal using the Wilcoxon signed rank test.
† Affected subjects without mutSCA1 or mutSCA3. mutSCA = Spinocerebellar ataxia gene mutations; HVA = homovanillic acid; 5-HIAA = 5-hydroxyindoleacetic acid.

Figure 3: Quantitative MRI findings in patients with autosomal dominant ataxia. (A) The cerebellum/posterior fossa ratio indicates the most atrophy in patients without mutSCA1 or mutSCA3 followed by those with mutSCA1, mutSCA3, and patients at risk for mutSCA3. (B) Pons/posterior fossa ratio and (C) the area of the cervical spinal cord indicate that these regions are relatively spared in patients without mutSCA1 or mutSCA3 and in patients at risk for mutSCA3. Data are averages of triplicate determinations (SEM) from two investigators.

Discussion

The postmortem lesions in the dominantly inherited ataxias show variable involvement of the substantia nigra, inferior olives, pontine nuclei, Purkinje cells, dentate nuclei, spinocerebellar tracts, anterior horn cells, and peripheral nerves. Presumably, the neuropathological and biochemical lesions seen in patients with mutSCA1 and mutSCA3 are not directly caused by their widely expressed gene products. Based on our MRI analysis, it seems that atrophy mainly occurs in the cerebellum in patients without mutSCA1 or mutSCA3. The cerebellum, pons, and spinal cord are all affected in patients with mutSCA1, and a spinopontine atrophy predominates in patients with mutSCA3. These MRI findings are in agreement with the neuropathological findings in patients with mutSCA1 and mutSCA3.10,12 The low concentrations of CSF HVA in patients with mutSCA1 and mutSCA3 correlate with the MRI findings, suggesting a more severe biochemical lesion affecting brainstem dopaminergic pathways. The slightly lower CSF concentrations of 5-HIAA in patients with mutSCA1 and mutSCA3 may also reflect a diminished contribution from the spinal cord and the cerebellar serotoninergic pathways. By contrast, in patients without mutSCA1 or mutSCA3 there does not seem to be a monoaminergic imbalance despite a “pure” cerebellar atrophy on MRI. Other investigators have documented reduced striatal enzyme concentrations of aromatic L-amino acid decarboxylase and tyrosine hydroxylase in patients with severe dopamine loss and a reduction in tyrosine hydroxylase but not aromatic L-amino acid decarboxylase in patients with moderate dopamine loss.17 These findings and our current data suggest that serotonin...
abnormalities in patients with mutSCA1 and mutSCA3 may reflect a functional variation of the serotonergic system under abnormal dopaminergic control. We suggest that this is the reason why patients with dominantly inherited ataxia do not respond to agents which alter serotonin metabolism.

To our knowledge, this is the first report describing serial measurements of biochemical, clinical, and radiological variables in patients with dominantly inherited ataxia. We have found by MRI that the degree of atrophy of the cerebellum, pons, and cervical spinal cord do not change over a one year period. It seems that lumbar CSF HVA concentrations and the total ACRS-rev scores could serve as meaningful biological markers to monitor progression of disease during therapeutic trials. Under the until the underlying pathogenetic mechanism of the CAG trinucleotide repeat expansion is unravelled, symptomatic treatment is currently the only option. Our data support the notion that combined treatment with serotonergic and dopaminergic agonists may improve the monoaminergic imbalance present in patients with mutSCA1 or mutSCA3. Interestingly, the MRI findings in those at risk for mutSCA3 indicate that the cerebellum may be the first neuroanatomical structure involved in the disease process. However, the relative paucity of abnormal histological findings in the cerebellum of patients with the mutSCA3 implies that the cerebellar afferents originating in the brainstem are the first areas targeted by the disease. The distinct topography of radiological and biochemical lesions in patients with various SCA mutations also suggests that there may be developmentally regulated injuries to the metencephalon by different genes, gene products, or modifier genes.


